Psilera Partners with Hesperos for Groundbreaking Dementia Treatment Development
Psilera, Inc., a pioneering biotechnology company, has recently entered into a strategic collaboration with Hesperos Inc., a leader in organ-on-a-chip technological advancements, to accelerate the development of PSIL-006, which targets frontotemporal dementia (FTD). This innovative partnership signifies a major milestone in Psilera's mission to create effective therapies for neurodegenerative disorders that have proven challenging to treat.
FTD is known for being a progressive neurodegenerative disorder, notoriously difficult to manage due to the limited options available for patients. By leveraging Hesperos' proprietary Human-on-a-Chip® platform—designed to integrate patient-derived induced pluripotent stem cells (iPSCs) into interconnected, multi-organ systems—the collaboration promises to enhance the precision of evaluating drug efficacy and safety. This advanced modeling approach not only streamlines the research process but has also received recognition from the FDA for its potential to reduce the reliance on animal testing, thus expediting the collection of clinic-ready datasets.
Dr. Jackie von Salm, Co-Founder and Chief Scientific Officer of Psilera, expressed her enthusiasm regarding the collaboration, emphasizing how this advanced platform will allow for an unprecedented understanding of PSIL-006's mechanism of action. This understanding is crucial as the therapeutic progresses toward its forthcoming first-in-human trials. The integration of such a sophisticated system aims to provide clearer insights into how PSIL-006 interacts with neural tissues, paving the way for more targeted and effective treatments.
Hesperos' innovative platform has garnered recognition for its capability to replicate human physiological responses, offering invaluable data on how drug candidates perform across various organ systems. The significant success of this system is apparent through its support of multiple Investigational New Drug (IND) and Orphan Drug Designation (ODD) applications, further establishing its utility in moving drug candidates closer to clinical trials.
Dr. James Hickman, Co-Founder and Chief Scientist at Hesperos, also shared his excitement regarding the collaboration, stating that it offers a unique opportunity to evaluate the impact of PSIL-006 on neural tissues derived from patients suffering from neurodegeneration. This could immensely accelerate the development of a much-needed therapy, especially in a field that is currently lacking effective solutions for such debilitating conditions.
With the aim of developing targeted treatments for the unmet medical needs within the realm of FTD, results from Psilera's preclinical modeling efforts are highly anticipated, with expectations set for Q3 2025. This timeline reflects the urgency and commitment that both companies have to innovation in the neurodegenerative disease space.
About Psilera:
Founded on the belief that innovative therapies can transform lives, Psilera is dedicated to developing groundbreaking therapeutics for hard-to-treat neurodegenerative diseases. Utilizing its proprietary neuroplastogen drug design platform, the company has built a robust pipeline, including its flagship product PSIL-006, which aims to revolutionize the treatment of FTD.
About Hesperos Inc:
Hesperos is a global contract research organization (CRO) that specializes in preclinical drug development using its Human-on-a-Chip® platform. This technology aims to replicate critical aspects of human biology, aimed at reducing costly and time-consuming animal testing while delivering meaningful insights into an agent's therapeutic potential.
As these two pioneering companies join forces, the future of FTD treatment looks promising, ushering in a new era of mindful medicine driven by innovative research and clinical excellence.
FTD is known for being a progressive neurodegenerative disorder, notoriously difficult to manage due to the limited options available for patients. By leveraging Hesperos' proprietary Human-on-a-Chip® platform—designed to integrate patient-derived induced pluripotent stem cells (iPSCs) into interconnected, multi-organ systems—the collaboration promises to enhance the precision of evaluating drug efficacy and safety. This advanced modeling approach not only streamlines the research process but has also received recognition from the FDA for its potential to reduce the reliance on animal testing, thus expediting the collection of clinic-ready datasets.
Dr. Jackie von Salm, Co-Founder and Chief Scientific Officer of Psilera, expressed her enthusiasm regarding the collaboration, emphasizing how this advanced platform will allow for an unprecedented understanding of PSIL-006's mechanism of action. This understanding is crucial as the therapeutic progresses toward its forthcoming first-in-human trials. The integration of such a sophisticated system aims to provide clearer insights into how PSIL-006 interacts with neural tissues, paving the way for more targeted and effective treatments.
Hesperos' innovative platform has garnered recognition for its capability to replicate human physiological responses, offering invaluable data on how drug candidates perform across various organ systems. The significant success of this system is apparent through its support of multiple Investigational New Drug (IND) and Orphan Drug Designation (ODD) applications, further establishing its utility in moving drug candidates closer to clinical trials.
Dr. James Hickman, Co-Founder and Chief Scientist at Hesperos, also shared his excitement regarding the collaboration, stating that it offers a unique opportunity to evaluate the impact of PSIL-006 on neural tissues derived from patients suffering from neurodegeneration. This could immensely accelerate the development of a much-needed therapy, especially in a field that is currently lacking effective solutions for such debilitating conditions.
With the aim of developing targeted treatments for the unmet medical needs within the realm of FTD, results from Psilera's preclinical modeling efforts are highly anticipated, with expectations set for Q3 2025. This timeline reflects the urgency and commitment that both companies have to innovation in the neurodegenerative disease space.
About Psilera:
Founded on the belief that innovative therapies can transform lives, Psilera is dedicated to developing groundbreaking therapeutics for hard-to-treat neurodegenerative diseases. Utilizing its proprietary neuroplastogen drug design platform, the company has built a robust pipeline, including its flagship product PSIL-006, which aims to revolutionize the treatment of FTD.
About Hesperos Inc:
Hesperos is a global contract research organization (CRO) that specializes in preclinical drug development using its Human-on-a-Chip® platform. This technology aims to replicate critical aspects of human biology, aimed at reducing costly and time-consuming animal testing while delivering meaningful insights into an agent's therapeutic potential.
As these two pioneering companies join forces, the future of FTD treatment looks promising, ushering in a new era of mindful medicine driven by innovative research and clinical excellence.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.